These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 36788591)

  • 1. Targeting ovarian cancer stem cells: a new way out.
    Ma H; Tian T; Cui Z
    Stem Cell Res Ther; 2023 Feb; 14(1):28. PubMed ID: 36788591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoparticle Delivery of TWIST Small Interfering RNA and Anticancer Drugs: A Therapeutic Approach for Combating Cancer.
    Glackin CA
    Enzymes; 2018; 44():83-101. PubMed ID: 30360816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of CD133-Sustained Chemoresistant Cancer Stem-Like Cells in Human Ovarian Carcinoma.
    Liu CL; Chen YJ; Fan MH; Liao YJ; Mao TL
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAD6 promotes DNA repair and stem cell signaling in ovarian cancer and is a promising therapeutic target to prevent and treat acquired chemoresistance.
    Somasagara RR; Spencer SM; Tripathi K; Clark DW; Mani C; Madeira da Silva L; Scalici J; Kothayer H; Westwell AD; Rocconi RP; Palle K
    Oncogene; 2017 Nov; 36(48):6680-6690. PubMed ID: 28806395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New markers for human ovarian cancer that link platinum resistance to the cancer stem cell phenotype and define new therapeutic combinations and diagnostic tools.
    Muñoz-Galván S; Felipe-Abrio B; García-Carrasco M; Domínguez-Piñol J; Suarez-Martinez E; Verdugo-Sivianes EM; Espinosa-Sánchez A; Navas LE; Otero-Albiol D; Marin JJ; Jiménez-García MP; García-Heredia JM; Quiroga AG; Estevez-Garcia P; Carnero A
    J Exp Clin Cancer Res; 2019 Jun; 38(1):234. PubMed ID: 31159852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flavonoids Restore Platinum Drug Sensitivity to Ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion.
    Koren Carmi Y; Mahmoud H; Khamaisi H; Adawi R; Gopas J; Mahajna J
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32906729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ovarian cancer stem cells: What progress have we made?
    Al-Alem LF; Pandya UM; Baker AT; Bellio C; Zarrella BD; Clark J; DiGloria CM; Rueda BR
    Int J Biochem Cell Biol; 2019 Feb; 107():92-103. PubMed ID: 30572025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EZH2 activates CHK1 signaling to promote ovarian cancer chemoresistance by maintaining the properties of cancer stem cells.
    Wen Y; Hou Y; Yi X; Sun S; Guo J; He X; Li T; Cai J; Wang Z
    Theranostics; 2021; 11(4):1795-1813. PubMed ID: 33408782
    [No Abstract]   [Full Text] [Related]  

  • 9. MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis.
    Zanotti L; Romani C; Tassone L; Todeschini P; Tassi RA; Bandiera E; Damia G; Ricci F; Ardighieri L; Calza S; Marchini S; Beltrame L; Tognon G; D'Incalci M; Pecorelli S; Sartori E; Odicino F; Ravaggi A; Bignotti E
    BMC Cancer; 2017 May; 17(1):366. PubMed ID: 28545541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer.
    Tayama S; Motohara T; Narantuya D; Li C; Fujimoto K; Sakaguchi I; Tashiro H; Saya H; Nagano O; Katabuchi H
    Oncotarget; 2017 Jul; 8(27):44312-44325. PubMed ID: 28574829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer.
    Deng J; Wang L; Chen H; Hao J; Ni J; Chang L; Duan W; Graham P; Li Y
    Oncotarget; 2016 Aug; 7(34):55771-55788. PubMed ID: 27304054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autotaxin Regulates Maintenance of Ovarian Cancer Stem Cells through Lysophosphatidic Acid-Mediated Autocrine Mechanism.
    Seo EJ; Kwon YW; Jang IH; Kim DK; Lee SI; Choi EJ; Kim KH; Suh DS; Lee JH; Choi KU; Lee JW; Mok HJ; Kim KP; Matsumoto H; Aoki J; Kim JH
    Stem Cells; 2016 Mar; 34(3):551-64. PubMed ID: 26800320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New insight into NANOG: A novel therapeutic target for ovarian cancer (OC).
    Mahalaxmi I; Devi SM; Kaavya J; Arul N; Balachandar V; Santhy KS
    Eur J Pharmacol; 2019 Jun; 852():51-57. PubMed ID: 30831081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting Cancer Stem Cells to Overcome Therapy Resistance in Ovarian Cancer.
    Muñoz-Galván S; Carnero A
    Cells; 2020 Jun; 9(6):. PubMed ID: 32512891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian cancer stem cells: ready for prime time?
    Sabini C; Sorbi F; Cunnea P; Fotopoulou C
    Arch Gynecol Obstet; 2020 Apr; 301(4):895-899. PubMed ID: 32200419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A traditional gynecological medicine inhibits ovarian cancer progression and eliminates cancer stem cells via the LRPPRC-OXPHOS axis.
    Jiang R; Chen Z; Ni M; Li X; Ying H; Fen J; Wan D; Peng C; Zhou W; Gu L
    J Transl Med; 2023 Jul; 21(1):504. PubMed ID: 37496051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
    Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
    Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD10
    Ffrench B; Gasch C; Hokamp K; Spillane C; Blackshields G; Mahgoub TM; Bates M; Kehoe L; Mooney A; Doyle R; Doyle B; O'Donnell D; Gleeson N; Hennessy BT; Stordal B; O'Riain C; Lambkin H; O'Toole S; O'Leary JJ; Gallagher MF
    Cell Death Dis; 2017 Oct; 8(10):e3128. PubMed ID: 29048400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoresistance in ovarian cancer: exploiting cancer stem cell metabolism.
    Li SS; Ma J; Wong AST
    J Gynecol Oncol; 2018 Mar; 29(2):e32. PubMed ID: 29468856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in the role of GPX3 in ovarian cancer (Review).
    Geng D; Zhou Y; Wang M
    Int J Oncol; 2024 Mar; 64(3):. PubMed ID: 38299269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.